The committee will help ensure Title21’s Cell and Gene Therapy Orchestration Platform continues to meet the broad needs of the rapidly accelerating industry
Phoenix, AZ, May 6, 2025 – Title21 Health Solutions, the software innovators for meeting life science regulatory needs, has named its inaugural Advisory Committee featuring five leaders from the cell and gene therapy (CGT) space, who bring a breadth of leadership, clinical, and entrepreneurial experience to support the company’s growth.
The committee includes:
- Dr. Stella Vnook, a distinguished pharmaceutical executive and serial entrepreneur with over 25 years of experience in the biotechnology and life sciences industries, including leadership positions at Merck & Co. She has founded multiple biotechs, and currently serves as CEO of Likarda, which is developing delivery technology to enhance cell therapies and other drug modalities.
- Dr. Elena Maryamchik, MD, MBA, a board-certified clinical pathologist specializing in transfusion medicine and cell therapy. She currently serves as the Director of the Cell Therapy Laboratory and Assistant Attending in Transfusion Medicine at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City.
- Jeff Liter, a seasoned executive who has overseen more than 20 clinical trials in CGT as the Chief Operating Officer at Progenitor Cell Therapy. He also served as the CEO of B-MoGen Biotechnologies, a cell therapy tools company, and led Luminary Therapeutics to an IND with a non-viral gene-modified therapy.
- Robb Richards, Corporate Director of The Center for Cell Therapy and Transplant program at Penn Medicine. Robb has over 20 years of experience in oncology, with past roles including IT Manager for the Center for Cancer and Hematologic Disease in Cherry Hill, Division Chief Operating Officer of Regional Cancer Care Associates (RCCA) in Cherry Hill, New Jersey, and RCCA corporate VP and Chief Information Officer.
- Caitlin Cahill, MSN MBA RN-BC, a Board-Certified Nurse with extensive apheresis experience, and the Administrative Director of Transfusion Medicine at Penn Medicine, University of Pennsylvania Health System, where she oversees the Blood Bank, Apheresis Unit, and Stem Cell Laboratory. She plays a key role in the onboarding of both commercial and research cell therapy products requiring apheresis and/or stem cell laboratory services.
“We welcome these distinguished leaders from across the CGT spectrum, who will help us define and chart the future of the CGT industry for our ultimate goal: helping patients,” said Tony Pare, CEO of Title21 Health Solutions. “This Advisory Committee is an extension of the highly experienced leadership team we have built at Title21.”
About Title21 Health Solutions
Title21 Health Solutions is an ArchiMed portfolio company. ArchiMed is a leading healthcare industry-focused growth equity enterprise based in New York and Lyon, France. Since 2001, Title21 Health Solutions has been dedicated to delivering easy-to-use, flexible, and integrated technology to support healthcare providers and the health sciences to achieve compliance, gain efficiencies and ensure high quality, ultimately, to support improvement in patient safety and care. The sole focus is developing technology to meet the specific needs of healthcare and life sciences firms, resulting in comprehensive solutions that are flexible to evolving business and regulatory requirements. Through the years, their partnerships with industry leaders have road-mapped their innovations to continue to meet the dynamic needs of the markets they serve. www.title21.com
